Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Darshan Mehta

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Clinicoeconomics and Outcomes Research : CEOR|April 28, 2021
Comparative Economic Outcomes in Patients with Focal Seizure Initiating First-Line Eslicarbazepine Acetate Monotherapy versus Generic Antiseizure DrugsDarshan Mehta, Matthew Davis, Andrew J Epstein, et al.
Journal of Immigrant and Minority Health|June 14, 2023
A Needs Assessment of Older Bangladeshi Immigrants in New York During the COVID-19 PandemicDipal Nagda, Kavya Pathak, Vivek Shah, et al.
Neurology and Therapy|April 7, 2021
Healthcare Resource Utilization Among Patients with Focal Seizures Treated with Eslicarbazepine Acetate in the US Long-Term Care Setting: A Retrospective Claims Database AnalysisDarshan Mehta, Drishti Shah, Vibha Desai, et al.
Epilepsy & Behavior : E&B|August 18, 2020
Associations between seizure severity change and patient characteristics, changes in seizure frequency, and health-related quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate: Post hoc analyses of clinical trial resultsJoyce A Cramer, Sam Colman, Kathryn P Anastassopoulos, et al.
Molecular Biology Reports|August 28, 2023
Epithelial-to-mesenchymal transition status correlated with ultrastructural features, and TP53 mutation in patient-derived oral cancer cell linesSushant S Navarange, Sanjay M Bane, Darshan Mehta, et al.
Human Cell|May 25, 2025
Establishment and molecular characterization of the novel cutaneous squamous cell carcinoma cell line from advanced-stage Indian patientDarshan Mehta, Akshay Paradkar, Prakash Nayak, et al.
Global Advances in Integrative Medicine and Health|December 2, 2024
Examining the Role of Medical School Faculty in Developing Students' Cultural Humility Skills: Insights From a Single-Center Multimethod StudyDhanesh D Binda, Angelique C Harris, Taralyn Tan, et al.
Toxicology and Applied Pharmacology|January 11, 2020
Characterizing biopersistence potential of the metabolite 5:3 fluorotelomer carboxylic acid after repeated oral exposure to the 6:2 fluorotelomer alcoholShruti V Kabadi, Jeffrey W Fisher, Daniel R Doerge, et al.
Epilepsy Research|February 8, 2021
Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizuresJohn Hixson, Barry Gidal, Andrei Pikalov, et al.
Journal of Medical Economics|July 27, 2021
Comparative economic outcomes in patients with focal seizures initiating eslicarbazepine acetate versus brivaracetam as their first adjunctive ASDDarshan Mehta, Matthew Davis, Andrew J Epstein, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Clinicoeconomics and Outcomes Research : CEOR|April 28, 2021
Comparative Economic Outcomes in Patients with Focal Seizure Initiating First-Line Eslicarbazepine Acetate Monotherapy versus Generic Antiseizure DrugsDarshan Mehta, Matthew Davis, Andrew J Epstein, et al.
Journal of Immigrant and Minority Health|June 14, 2023
A Needs Assessment of Older Bangladeshi Immigrants in New York During the COVID-19 PandemicDipal Nagda, Kavya Pathak, Vivek Shah, et al.
Neurology and Therapy|April 7, 2021
Healthcare Resource Utilization Among Patients with Focal Seizures Treated with Eslicarbazepine Acetate in the US Long-Term Care Setting: A Retrospective Claims Database AnalysisDarshan Mehta, Drishti Shah, Vibha Desai, et al.
Epilepsy & Behavior : E&B|August 18, 2020
Associations between seizure severity change and patient characteristics, changes in seizure frequency, and health-related quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate: Post hoc analyses of clinical trial resultsJoyce A Cramer, Sam Colman, Kathryn P Anastassopoulos, et al.
Molecular Biology Reports|August 28, 2023
Epithelial-to-mesenchymal transition status correlated with ultrastructural features, and TP53 mutation in patient-derived oral cancer cell linesSushant S Navarange, Sanjay M Bane, Darshan Mehta, et al.
Human Cell|May 25, 2025
Establishment and molecular characterization of the novel cutaneous squamous cell carcinoma cell line from advanced-stage Indian patientDarshan Mehta, Akshay Paradkar, Prakash Nayak, et al.
Global Advances in Integrative Medicine and Health|December 2, 2024
Examining the Role of Medical School Faculty in Developing Students' Cultural Humility Skills: Insights From a Single-Center Multimethod StudyDhanesh D Binda, Angelique C Harris, Taralyn Tan, et al.
Toxicology and Applied Pharmacology|January 11, 2020
Characterizing biopersistence potential of the metabolite 5:3 fluorotelomer carboxylic acid after repeated oral exposure to the 6:2 fluorotelomer alcoholShruti V Kabadi, Jeffrey W Fisher, Daniel R Doerge, et al.
Epilepsy Research|February 8, 2021
Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizuresJohn Hixson, Barry Gidal, Andrei Pikalov, et al.
Journal of Medical Economics|July 27, 2021
Comparative economic outcomes in patients with focal seizures initiating eslicarbazepine acetate versus brivaracetam as their first adjunctive ASDDarshan Mehta, Matthew Davis, Andrew J Epstein, et al.
Pageof 5